Give Online: Help shape patient care for generations to come.



Request an Appointment



Contact us with Questions

Expand Content

Clinical Trials

Use of 3,4-Diaminopyridine in Lambert Eaton Syndrome

Compassionate use of orphan drug 3,4-Diaminopyridine (DAP) in Treatment of Lambert Eaton Myasthenic Syndrome (LEMS). The purpose of the drug is to decrease the muscle weakness and other symptoms of Lambert Eaton Syndrome.Traditionally patients are treated with immunosuppressive agents such as Prednisone. The general guidelines for the use of this drug include taking the drug by mouth at increasing dosages until a clinical effect is seen. The duration of the use of this drug will depend upon whether you see benefit from it, and whether any side effects from the drug prevent you from wishing to continue. Additional inclusion and exclusion criteria apply.

If you have any questions or would like more information please contact Fran Greenfield, Clinical Research Coordinator at 216.445.1109.

This study is being conducted by Dr. Kerry Levin at the Cleveland Clinic Neurological Institute.